CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 63 enrolled
Drug / intervention
LY3316531 - IV +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03418493
NCT03418493Phase 1Completed
CompareCT.gov

A Phase 1 Randomized, Placebo-Controlled Study of LY3316531 in Healthy Subjects and an Open-Label, Single-Dose Study in Patients With Psoriasis

Eli Lilly and Company·interventional·Posted Feb 1, 2018·Updated Sep 21, 2023

In Brief

A Phase 1 clinical trial evaluating LY3316531 - IV, LY3316531 - SC, and 1 other intervention for Psoriasis. Completed, enrolled 63 participants across 2 sites.

Detailed Summary

The purpose of this study is to evaluate how well LY3316531 is tolerated and what side effects may occur in healthy participants and participants with psoriasis. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). This is a three-part study. Participants will enroll in only one part. Parts A and B are for healthy participants and Part C is for participants with psoriasis. Participation could last between 16 and 57 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedFeb 1, 2018
Enrollment StartJan 30, 2018
Primary CompletionDec 24, 2018
Study CompletionJul 29, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.4 years ago

Interventions

LY3316531 - IVdrug

Administered IV.

LY3316531 - SCdrug

Administered SC.

Placebo - IVdrug

Administered IV.